Evidence map›Paper›PMID 37603819›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?

Benjamin Y Lu, Sarah B Goldberg

Open access · bronzeAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Benjamin Y LuDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT.ORCID 0000-0001-8764-8384
Sarah B GoldbergDepartment of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT.ORCID 0000-0002-0920-1381
Yale University · US

Funding

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Shuangge Ma · 2015 to 2026
$31.1M
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMK12CA215110 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · 2018 to 2026
$6.1M
Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)T32CA233414 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 2019 to 2026
$3.2M
NCI NIH HHS K12 CA215110NCI NIH HHS P50 CA196530NCI NIH HHS T32 CA233414
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsLung NeoplasmsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsHumansImmunotherapyAntineoplastic Agents, Immunological

Identifiers

PMID37603819
OpenAlexW4386023077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.